Edition:
India

Synlogic Announces Collaboration To Evaluate Synb1891 In Combination With Pd-L1 In Patients With Advanced Solid Tumors


Wednesday, 22 May 2019 

May 22 (Reuters) - Synlogic Inc ::SYNLOGIC ANNOUNCES CLINICAL COLLABORATION TO EVALUATE SYNB1891 IN COMBINATION WITH PD-L1 CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS.SYNLOGIC - COLLABORATION WITH ROCHE TO EXPLORE CO'S SYNTHETIC BIOTIC MEDICINE, SYNB1891 IN COMBINATION WITH ROCHE'S PD-L1-BLOCKING CHECKPOINT INHIBITOR ATEZOLIZUMAB.SYNLOGIC INC - EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION WITH FDA IN SECOND HALF OF 2019 FOR SYNB1891.